Suscribirse

Is the economic and social cost of one-stage bilateral hip resurfacing lower than two-stage procedures? Retrospective case-control study of 260 hips - 25/04/20

Doi : 10.1016/j.otsr.2020.01.011 
Antoine Hoestlandt a, c, , Julien Dartus a, c, Cyril Delay a, c, Pierre Martinot a, c, Julien Girard a, b, c
a Université Lille Nord de France, 59000 Lille, France 
b Département de médecine du sport, faculté de médecine de Lille, université Lille 2, 59000 Lille, France 
c Service d’orthopédie C, hôpital Salengro, CHU de Lille, place de Verdun, 59000 Lille, France 

Corresponding author at: 199, rue Anatole-France, 6,9100 Villeurbanne, France.199, rue Anatole-FranceVilleurbanne6,9100France

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

Studies on the economic impact of medical practices and estimates of intra- and extra-hospital costs have an important role in controlling healthcare spending. But few studies of this nature have been done for bilateral surgery in a single operative session. This led us to carry out a health economics study to determine whether (1) bilateral hip resurfacing arthroplasty (HRA) performed in one stage instead of two stages will reduce the health care expenditures (costs of hospitalization, medical leave, rehabilitation), (2) it is equally safe for the patient.

Hypothesis One-stage bilateral HRA is less costly for the health care system than two-stage bilateral resurfacing.

Methods

This was a single-center, single-surgeon retrospective cohort study comparing patients who underwent bilateral HRA in one stage (53 cases) or in two stages (77 cases). We determined the intra-hospital costs based on the French National Cost Scales and the extra-hospital costs (medical leave and rehabilitation), perioperative data (blood loss, operation time, duration of narcotic analgesic use, medical and surgical complications) and the outcomes with a mean follow-up of 4.8 years [1.7–10.1].

Results

The total costs for the one-stage group (€16,840.94±7042.7) were significantly less than those of the two-stage group (€19,335.0±7296.9) (p=0.0101). The two groups were comparable except for the one-stage group having more primary hip osteoarthritis indications (72% (38/53)) than the two-stage group (49% (38/77)) (p=0.0111). The main differences between groups was the cost and duration of hospitalization, with cost of €10,546.06±2049.47 and average length of stay (ALS) of 9.83±2.19 days in the one-stage group and €13,569.49±2186.30, ALS=15.04±3.15 days in the two-stage group (p<0.0001). There was no significant difference in the length of medical leave: 67.15±50.36 (0–180) days for the one-stage group and 97.89±108.39 (0–730) days for the two-stage group (p=0.1933).

Conclusion

Performing bilateral HRA during a single hospital stay results in lower health care expenditures than performing it during two separate hospital stays. Similar studies on other surgical procedures could help to promote the simultaneous nature of bilateral procedures and reset the current pricing, which is currently too low in the French health care system.

Level of evidence

III, Retrospective case-control study.

El texto completo de este artículo está disponible en PDF.

Keywords : Hip resurfacing, Bilateral, Cost analysis, One-stage versus two-stage


Esquema


© 2020  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 106 - N° 3

P. 535-542 - mai 2020 Regresar al número
Artículo precedente Artículo precedente
  • Hip resurfacing generates a more physiological gait than total hip replacement: A case-control study
  • Cedric Maillot, Edouard Auvinet, Ciara Harman, Justin Cobb, Charles Rivière
| Artículo siguiente Artículo siguiente
  • Modification of regional bone mineral density due to femoral rasping in cementless proximally fixed total hip arthroplasty
  • Ibraheim El-Daly, Andres Rondon, Stefroy Pinto, Christine Chappard, Quentin Grimal, Elhadi Sariali

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.